In Vitro Dissolution Profile Comparison—Statistics and Analysis of the Similarity Factor, f2

Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland 20852, USA.
Pharmaceutical Research (Impact Factor: 3.42). 07/1998; 15(6):889-96. DOI: 10.1023/A:1011976615750
Source: PubMed


To describe the properties of the similarity factor (f2) as a measure for assessing the similarity of two dissolution profiles. Discuss the statistical properties of the estimate based on sample means.
The f2 metrics and the decision rule is evaluated using examples of dissolution profiles. The confidence interval is calculated using bootstrapping method. The bias of the estimate using sample mean dissolution is evaluated.
1. f2 values were found to be sensitive to number of sample points, after the dissolution plateau has been reached. 2. The statistical evaluation of f2 could be made using 90% confidence interval approach. 3. The statistical distribution of f2 metrics could be simulated using 'Bootstrap' method. A relatively robust distribution could be obtained after more than 500 'Bootstraps'. 4. A statistical 'bias correction' was found to reduce the bias.
The similarity factor f2 is a simple measure for the comparison of two dissolution profiles. But the commonly used similarity factor estimate f2 is a biased and conservative estimate of f2. The bootstrap approach is a useful tool to simulate the confidence interval.

347 Reads
  • Source
    • "Another study of Maggi et al. (Maggi et al., 2000), indicated that DTZ in a matrix tablet containing PEO was stable after one year storage at room temperature. Figure 3 depicted that all tablets were found to be stable after five-year storage as indicated by the value of (ƒ 2 ) (≥ 50) (FDA, 1997; Shah et al., 1998). Meanwhile, the similarity factor (ƒ 2 ) values between the fresh and the stored tablets were decreased as PEO M W increased (ƒ 2 = 96, 70 and 56 for F1, F2 and F3, respectively, Figure 3), indicating a sign for the decrease in system stability as PEO M W increased. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study is to investigative the stability of poly(ethylene oxide) (PEO) matrix tablets containing diltiazem hydrochloride (DTZ) after five-year storage at room temperature. DTZ matrix tablets containing different molecular weights (MW) of PEO and electrolytes (sodium carbonate anhydrous Na2CO3, potassium chloride KCl and pentasodium tripolyphosphate anhydrous PSTPP) were prepared. The fresh and stored tablets were evaluated by DTZ content, in vitro drug release rates and kinetics as well as DSC. All the PEO's matrix tablets showed no significant changes in release rate, kinetics and drug content. The release rates of DTZ following five-year storage were slightly increased as the MW of PEO increased from 900,000 to 8,000,000. Also, it was clear that the addition of electrolyte drastically slowed the release rates of DTZ from fresh and stored tablets. DSC thermograms and similarity factor (ƒ2) depicted good system stability for all stored tablets. This is the first five-year long-term stability study reported concerning DTZ/PEO matrix tablets with different MW, which proved its stability for several years. This study might throw light on the dramatic difference observed between this study and the reported data of accelerated stability testing under stress conditions found in the literature.
    Journal of Applied Pharmaceutical Science 08/2015; 5(07):12-22. DOI:10.7324/JAPS.2015.50703 · 0.47 Impact Factor
  • Source
    • "similarity factor, f 2 , aligns with the model results indicating similar in vivo release of the two products. In addition to quantitatively describing the similarity of the two dissolution curves, the f 2 is sensitive to large differences in any particular time point [11]. The results of this analysis support findings from clinical trials in China [1] as well as more recent study results indicating that Sino-implant (II) performs as well as Jadelle in the first year of use. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Measuring the amount of progestin remaining in contraceptive implants used for different lengths of time provides useful information on in vivo release kinetics including change over time. We compared estimated in-vivo levonorgestrel (LNG) release rates derived from Sino-implant (II) explants with similar data from removed Jadelle. We measured LNG remaining in 44 sets of Sino-implant (II) used for up to seven years and removed in four Chinese clinics. Results were compared with published data for Jadelle explants used for up to 36 months. We estimated and compared monthly and daily LNG release rates for the two products using prediction models for drug release. We also estimated the dissolution profile similarity factor, f2, for LNG release. Both Sino-implant (II) and Jadelle release approximately 30% of total LNG load after three years. Results of fitting the data to a biologically plausible modified Higuchi prediction model indicate comparable release through three years. An estimated similarity factor of 80.6 (90% CI: 70.8-85.7) indicates similarity in the dissolution profiles of the two implants. LNG release in-vivo measured through explant analysis suggest that Sino-implant (II) and Jadelle may perform similarly through three years of use and could remain highly effective beyond this time point. These results align with published data for Jadelle and Sino-implant (II) showing high effectiveness for five years. Ongoing clinical studies comparing the products over five years present an opportunity to verify this supportive measure of clinical effectiveness. This innovative approach provides evidence that Sino-implant (II) may perform clinically similarly to Jadelle over three years and remain a highly effective contraceptive beyond this time point. Data from explant analyses show promise for investigating the equivalence of elusion profiles of contraceptive implants. Copyright © 2015. Published by Elsevier Inc.
    Contraception 07/2015; 81. DOI:10.1016/j.contraception.2015.06.028 · 2.34 Impact Factor
  • Source
    • "Structure of PEA III Ac Bz. analyzed with SEM during the first two weeks. Sterilized and nonsterilized DX-loaded microspheres' release profiles were compared with the evaluation of the similarity factor f 2 [16] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Most of the posterior segment diseases are chronic and multifactorial and require long-term intraocular medication. Conventional treatments of these pathologies consist of successive intraocular injections, which are associated with adverse effects. Successful therapy requires the development of new drug delivery systems able to release the active substance for a long term with a single administration. The present work involves the description of a new generation of microspheres based on poly (ester amide)s (PEA), which are novel polymers with improved biodegradability, processability and good thermal and mechanical properties. We report on the preparation of the PEA polymer, PEA microspheres (PEA Ms) and their characterization. PEA Ms (~15μm) were loaded with a lipophilic drug (dexamethasone) (181.0±2.4μg DX/mg Ms). The in vitro release profile of the drug showed a constant delivery for at least 90days. Based on the data from a performed in vitro release study, a kinetic ocular model to predict in vivo drug concentrations in a rabbit vitreous was built. According to the pharmacokinetic simulations, intravitreal injection of dexamethasone loaded PEA microspheres would provide release of the drug in rabbit eyes up to 3 months. Cytotoxicity studies in macrophages and retinal pigment epithelial cells revealed a good in vitro tolerance of the microsystems. After sterilization, PEA Ms were administered in vivo by subtenon and intravitreal injections in male Sprague-Dawley rats and the location of the microspheres in rat eyes was monitored. We conclude that PEA Ms provide an alternative delivery system for controlling the delivery of drugs to the eye, allowing a novel generation of microsphere design. Copyright © 2015. Published by Elsevier B.V.
    Journal of Controlled Release 05/2015; 211. DOI:10.1016/j.jconrel.2015.05.279 · 7.71 Impact Factor
Show more